Abstract
ABSTRACTChronic obstructive pulmonary disease (COPD), whose main risk factor is cigarette smoking (CS), is one of the most common diseases globally. Many COPD patients also develop pulmonary hypertension (PH), a severe complication that leads to premature death. Evidence suggests reactive oxygen species (ROS) involvement in COPD and PH, especially regarding pulmonary artery smooth muscle cells (PASMC) dysfunction. However, the effects of CS on the pulmonary vasculature are not completely understood. Herein we provide evidence on the effects of CS extract (CSE) exposure on PASMC regarding ROS production, antioxidant response and its consequences on vascular tone dysregulation. Our results indicate that CSE exposure promotes mitochondrial fission, mitochondrial membrane depolarization and increased mitochondrial superoxide levels. However, the increase in superoxide did not parallel a counterbalancing antioxidant response in human pulmonary artery (PA) cells. Interestingly, the mitochondrial superoxide chelator mitoTEMPO reduced mitochondrial fission and membrane potential depolarization caused by CSE. As we have previously shown, CSE reduces PA vasoconstriction and vasodilation. In this respect, mitoTEMPO prevented the impaired nitric oxide-mediated vasodilation, while vasoconstriction remained reduced. Finally, we observed a CSE-driven downregulation of the Cyb5R3 enzyme, which prevents soluble guanylyl cyclase oxidation in PASMC. This might explain the CSE-mediated decrease in PA vasodilation. These results provide evidence that there might be a connection between mitochondrial ROS and altered vasodilation responses in PH secondary to COPD, and strongly support the potential of antioxidant strategies specifically targeting mitochondria as a new therapy for these diseases.Graphical abstract
Publisher
Cold Spring Harbor Laboratory
Reference81 articles.
1. Global strategy for diagnosis, management and prevention of C. 2021 GOLD Reports - Global Initiative for Chronic Obstructive Lung Disease - GOLD. (2021). Available at: https://goldcopd.org/2021-gold-reports/%0A https://goldcopd.org/gold-reports/%0A https://goldcopd.org/2021-gold-reports/. (Accessed: 24th November 2017)
2. Epidemiology and clinical impact of major comorbidities in patients with COPD;Int. J. COPD,2014
3. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives
4. Out of proportion pulmonary hypertension in obstructive lung diseases;Current Opinion in Pulmonary Medicine,2018
5. Hemodynamic Characterization of Patients with Severe Emphysema